Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:847-852
Published online before print March 13, 2003, doi: 10.1161/01.ATV.0000066133.32063.BB
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
23/5/847    most recent
01.ATV.0000066133.32063.BBv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Asztalos, B. F.
Right arrow Articles by Schaefer, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Asztalos, B. F.
Right arrow Articles by Schaefer, E. J.
Related Collections
Right arrow Endothelium/vascular type/nitric oxide
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:847.)
© 2003 American Heart Association, Inc.


Atherosclerosis and Lipoproteins

Change in {alpha}1 HDL Concentration Predicts Progression in Coronary Artery Stenosis

Bela F. Asztalos; Marcelo Batista; Katalin V. Horvath; Caitlin E. Cox; Gerard E. Dallal; Josh S. Morse; Greg B. Brown; Ernst J. Schaefer

From the Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Center on Aging at Tufts University and Division of Endocrinology, Metabolism, Diabetes, and Molecular Medicine (B.F.A., M.B., K.V.H., C.E.C., G.E.D., E.J.S.), New England Medical Center, Boston, Mass, and Department of Medicine, Division of Cardiology (J.S.M., G.B.B.), University of Washington, Seattle, Wash.

Correspondence to Bela F. Asztalos, PhD, JM-USDA/HNRC at Tufts University, Lipid Metabolism Laboratory, 711 Washington St, Boston, MA 02111. E-mail bela.asztalos{at}tufts.edu

Objective— We examined the effects of simvastatin-niacin and antioxidant vitamins on changes in high-density lipoprotein (HDL) subpopulations and alterations in coronary artery stenosis, as assessed by angiography.

Methods and Results— Lipids, lipoproteins, and HDL particles were measured on and off treatment in 123 subjects of the HDL-Atherosclerosis Treatment Study. Patients were assigned to 4 treatment groups, simvastatin-niacin, simvastatin-niacin-antioxidant vitamins, antioxidant vitamins, and placebo. Subjects were followed for 3 years on treatment and then for 2 months off treatment. Simvastatin-niacin significantly increased the 2 large apoA-I–containing HDL subpopulations, {alpha}1 and pre{alpha}1, and significantly decreased the 2 smallest particles, preß1 and {alpha}3, compared with values obtained from the same patients off treatment. Adding antioxidant vitamins to the lipid-modifying agents blunted these effects (not significant). A significant negative correlation (r=-0.235; P<0.01) between the changes in {alpha}1 HDL particle concentration and coronary artery stenosis was noted. Subjects in the third tertile (157% increase in {alpha}1) had no progression of stenosis in the 3-year follow-up period, whereas subjects in the first tertile (15% decrease in {alpha}1) had an average of 2.1% increase in stenosis.

Conclusions— Simvastatin-niacin therapy significantly increased the large apoA-I–containing {alpha}1 HDL particles. This increase was significantly associated with less progression of coronary stenosis even after adjusting for traditional risk factors.


Key Words: HDL subpopulations • coronary heart disease • coronary stenosis • statin • niacin




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Lamon-Fava, M. R. Diffenderfer, P. H. R. Barrett, A. Buchsbaum, M. Nyaku, K. V. Horvath, B. F. Asztalos, S. Otokozawa, M. Ai, N. R. Matthan, et al.
Extended-Release Niacin Alters the Metabolism of Plasma Apolipoprotein (Apo) A-I and ApoB-Containing Lipoproteins
Arterioscler. Thromb. Vasc. Biol., September 1, 2008; 28(9): 1672 - 1678.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
R. Movva and D. J. Rader
Laboratory Assessment of HDL Heterogeneity and Function
Clin. Chem., May 1, 2008; 54(5): 788 - 800.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Lamon-Fava, D. M. Herrington, D. M. Reboussin, M. Sherman, K. V. Horvath, L. A. Cupples, C. White, S. Demissie, E. J. Schaefer, and B. F. Asztalos
Plasma Levels of HDL Subpopulations and Remnant Lipoproteins Predict the Extent of Angiographically-Defined Coronary Artery Disease in Postmenopausal Women
Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): 575 - 579.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
R. D. Santos, E. J. Schaefer, B. F. Asztalos, E. Polisecki, J. Wang, R. A. Hegele, L. R. C. Martinez, M. H. Miname, C. E. Rochitte, P. L. Da Luz, et al.
Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency
J. Lipid Res., February 1, 2008; 49(2): 349 - 357.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
A. Kontush and M. J. Chapman
Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis
Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
B. F. Asztalos, M. de la Llera-Moya, G. E. Dallal, K. V. Horvath, E. J. Schaefer, and G. H. Rothblat
Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux
J. Lipid Res., October 1, 2005; 46(10): 2246 - 2253.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
V. Nambi and C. M. Ballantyne
Fat, Fit, and Leading the Charge: The Evolution of Measuring High-Density Lipoprotein Subpopulations
Arterioscler. Thromb. Vasc. Biol., October 1, 2005; 25(10): 2013 - 2015.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
B. F. Asztalos, D. Collins, L. A. Cupples, S. Demissie, K. V. Horvath, H. E. Bloomfield, S. J. Robins, and E. J. Schaefer
Value of High-Density Lipoprotein (HDL) Subpopulations in Predicting Recurrent Cardiovascular Events in the Veterans Affairs HDL Intervention Trial
Arterioscler. Thromb. Vasc. Biol., October 1, 2005; 25(10): 2185 - 2191.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. E. Brousseau, M. R. Diffenderfer, J. S. Millar, C. Nartsupha, B. F. Asztalos, F. K. Welty, M. L. Wolfe, M. Rudling, I. Bjorkhem, B. Angelin, et al.
Effects of Cholesteryl Ester Transfer Protein Inhibition on High-Density Lipoprotein Subspecies, Apolipoprotein A-I Metabolism, and Fecal Sterol Excretion
Arterioscler. Thromb. Vasc. Biol., May 1, 2005; 25(5): 1057 - 1064.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
B. F. Asztalos, L. A. Cupples, S. Demissie, K. V. Horvath, C. E. Cox, M. C. Batista, and E. J. Schaefer
High-Density Lipoprotein Subpopulation Profile and Coronary Heart Disease Prevalence in Male Participants of the Framingham Offspring Study
Arterioscler. Thromb. Vasc. Biol., November 1, 2004; 24(11): 2181 - 2187.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
B. Olchawa, B. A. Kingwell, A. Hoang, L. Schneider, O. Miyazaki, P. Nestel, and D. Sviridov
Physical Fitness and Reverse Cholesterol Transport
Arterioscler. Thromb. Vasc. Biol., June 1, 2004; 24(6): 1087 - 1091.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
B. F. Asztalos, K. V. Horvath, K. Kajinami, C. Nartsupha, C. E. Cox, M. Batista, E. J. Schaefer, A. Inazu, and H. Mabuchi
Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency
J. Lipid Res., March 1, 2004; 45(3): 448 - 455.
[Abstract] [Full Text] [PDF]